Immunologically relevant aspects of the new COVID-19 vaccines—an ÖGAI (Austrian Society for Allergology and Immunology) and AeDA (German Society for Applied Allergology) position paper

Untersmayr, Eva; Förster-Waldl, Elisabeth; Bonelli, Michael; Boztuğ, Kaan; Brunner, Patrick M.; Eiwegger, Thomas; Eller, Kathrin; Göschl, Lisa; Grabmeier‐Pfistershammer, Katharina; Hötzenecker, Wolfram; Jordakieva, Galateja; Moschen, Alexander R.; Pfaller, Birgit; Pickl, Winfried F.; Reinisch, Walter; Wiedermann, Ursula; Klimek, Ludger; Bergmann, Karl‐Christian; Pfützner, Wolfgang; Novak, Natalija; Rabe, Uta; Schlenter, Wolfgang; Ring, Johannes; Wehrmann, Wolfgang; Mülleneisen, Norbert; Wrede, Holger; Fuchs, Thomas; Jensen‐Jarolim, Erika

doi:10.1007/s40629-021-00178-2

Cited by 7 publications

(7 citation statements)

References 76 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These points have been categorized in the table as depicted below: For patients with autoimmune disorders Autoimmune inflammatory rheumatic diseases 82 , 83 , 84 , 85 , 86 , 87 Psoriasis 88 , 89 Hidradenitis suppurativa 90 Patients with pemphigus on rituximab 91 Inflammatory bowel diseases 92 For patients with allergic or atopic disorders Atopic dermatitis 93 , 94 , 95 Mastocytosis 96 , 97 Urticaria 93 , 94 Allergic diseases (general) 98 , 99 , 100 , 101 , 102 , 103 Precautions for anaphylaxis 104 , 105 , 106 , 107 , 108 For dermatology patients on Immunosuppressive, immunomodulatory or biologic therapies 109 , 110 , 111 , 112 , 113 Precautions for vaccine‐induced thrombotic thrombocytopenia 72 , 114 …”

Section: Resultsmentioning

confidence: 99%

“…For patients with allergic or atopic disorders Atopic dermatitis 93 , 94 , 95 Mastocytosis 96 , 97 Urticaria 93 , 94 Allergic diseases (general) 98 , 99 , 100 , 101 , 102 , 103 Precautions for anaphylaxis 104 , 105 , 106 , 107 , 108 …”

Section: Resultsmentioning

confidence: 99%

“…2.3 Urticaria 93,94 2.4 Allergic diseases (general) [98][99][100][101][102][103] 2.5 Precautions for anaphylaxis [104][105][106][107][108] 3. For dermatology patients on Immunosuppressive, immunomodulatory or biologic therapies [109][110][111][112][113] 4.…”

Section: Recommendations and Guidelines For Vaccination In Specific G...mentioning

confidence: 99%

See 2 more Smart Citations

A systematic review on mucocutaneous presentations after COVID‐19 vaccination and expert recommendations about vaccination of important immune‐mediated dermatologic disorders

Seirafianpour

Pourriyahi

Mesgarha

et al. 2022

Dermatologic Therapy

View full text Add to dashboard Cite

With dermatologic side effects being fairly prevalent following vaccination against COVID‐19, and the multitude of studies aiming to report and analyze these adverse events, the need for an extensive investigation on previous studies seemed urgent, in order to provide a thorough body of information about these post‐COVID‐19 immunization mucocutaneous reactions. To achieve this goal, a comprehensive electronic search was performed through the international databases including Medline (PubMed), Scopus, Cochrane, Web of science, and Google scholar on July 12, 2021, and all articles regarding mucocutaneous manifestations and considerations after COVID‐19 vaccine administration were retrieved using the following keywords: COVID‐19 vaccine, dermatology considerations and mucocutaneous manifestations. A total of 917 records were retrieved and a final number of 180 articles were included in data extraction. Mild, moderate, severe and potentially life‐threatening adverse events have been reported following immunization with COVID vaccines, through case reports, case series, observational studies, randomized clinical trials, and further recommendations and consensus position papers regarding vaccination. In this systematic review, we categorized these results in detail into five elaborate tables, making what we believe to be an extensively informative, unprecedented set of data on this topic. Based on our findings, in the viewpoint of the pros and cons of vaccination, mucocutaneous adverse events were mostly non‐significant, self‐limiting reactions, and for the more uncommon moderate to severe reactions, guidelines and consensus position papers could be of great importance to provide those at higher risks and those with specific worries of flare‐ups or inefficient immunization, with sufficient recommendations to safely schedule their vaccine doses, or avoid vaccination if they have the discussed contra‐indications.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

A systematic review on mucocutaneous presentations after COVID‐19 vaccination and expert recommendations about vaccination of important immune‐mediated dermatologic disorders

Seirafianpour

Pourriyahi

Mesgarha

et al. 2022

Dermatologic Therapy

View full text Add to dashboard Cite

show abstract

“…Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes respiratory and general illness with coronavirus disease 2019 (COVID-19) [ 7 – 10 ]. The COVID-19 pandemic is the most serious public health crisis of this decade, with nearly 300 million people sickened worldwide and approximately 5.5 million deaths ( www.worldometers.info/coronavirus/ [as of January 7, 2022]).…”

Section: Prevalence and Presentation Of Olfactory Loss In Covid-19mentioning

confidence: 99%

Olfactory and gustatory disorders in COVID-19

et al. 2022

Self Cite

View full text Add to dashboard Cite

SummaryLoss of olfaction is one of the symptoms most commonly reported by patients with coronavirus disease 2019 (COVID-19). Although the spontaneous recovery rate is high, recent studies have shown that up to 7% of patients remain anosmic for more than 12 months after the onset of infection, leaving millions of people worldwide suffering from severe olfactory impairment. Olfactory training remains the first recommended treatment. With the continued lack of approved drug treatments, new therapeutic options are being explored. This article reviews the current state of science on COVID-19-related olfactory disorders, focusing on epidemiology, pathophysiology, cure rates, currently available treatment options, and research on new treatments.

show abstract

“…Guidelines for diagnosis and treatment of anaphylactic reactions to SARS-CoV‑2 vaccines have been developed by several medical societies [ 32 , 33 ].…”

Section: Anaphylaxismentioning

confidence: 99%

Cutaneous and hypersensitivity reactions associated with COVID-19 vaccination—a narrative review

Wollina

Chiriac

Kocic

et al. 2021

Wien Med Wochenschr

View full text Add to dashboard Cite

Vaccination against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV‑2) has become a major tool in the battle against the coronavirus disease 2019 (COVID-19) pandemic. Numerous products have been developed and more are to come. Vaccination success varies greatly between different countries. There are a number of different vaccine types, such as mRNA, DNA vaccines, adenovirus vector vaccines, and full-length spike protein nanoparticles with a special matrix. The different types may also cause a different spectrum of adverse events. With mass vaccination, post-marketing surveillance for product safety becomes increasingly important. In this review, we discuss possible hypersensitivity and cutaneous adverse events related to SARS-CoV‑2 vaccination—from local reactions like COVID arm to systemic and severe reactions like anaphylaxis. Vaccination may also induce or exacerbate preexisting disorders such as herpes zoster infection. This review should provide information to tailor, whenever possible, vaccination to patients’ needs. It is a contribution to patient safety as well. There is general consensus that the benefits of SARS-CoV‑2 vaccination currently outweigh the risks of possible adverse events.

show abstract

Immunologically relevant aspects of the new COVID-19 vaccines—an ÖGAI (Austrian Society for Allergology and Immunology) and AeDA (German Society for Applied Allergology) position paper

Cited by 7 publications

References 76 publications

A systematic review on mucocutaneous presentations after COVID‐19 vaccination and expert recommendations about vaccination of important immune‐mediated dermatologic disorders

A systematic review on mucocutaneous presentations after COVID‐19 vaccination and expert recommendations about vaccination of important immune‐mediated dermatologic disorders

Olfactory and gustatory disorders in COVID-19

Cutaneous and hypersensitivity reactions associated with COVID-19 vaccination—a narrative review

Contact Info

Product

Resources

About